For the year ending 2025-12-31, PHAT made $175,110K in revenue. -$221,247K in net income. Net profit margin of -126.35%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Product revenue, net | 175,110 | 55,252 | ||
| Cost of revenue | 22,599 | 7,973 | ||
| Gross profit | 152,511 | 47,279 | ||
| Research and development | 32,780 | 34,082 | ||
| Selling, general and administrative | 279,717 | 290,664 | ||
| Total operating expenses | 312,497 | 324,746 | ||
| Loss from operations | -159,986 | -277,467 | ||
| Interest income | 7,044 | 15,158 | ||
| Interest expense | 68,115 | 72,009 | ||
| Other expense, net | -190 | -8 | ||
| Total other expense | -61,261 | -56,859 | ||
| Net loss and comprehensive loss | -221,247 | -334,326 | ||
| Basic EPS | -3.03 | -5.29 | ||
| Diluted EPS | -3.03 | -5.29 | ||
| Basic Average Shares | 72,918,764 | 63,176,210 | ||
| Diluted Average Shares | 72,918,764 | 63,176,210 | ||
Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT)